Odivo as a new complementary treatment for removable NSCLC

Meishi Shiguibao recently announced that the phase III clinical study CheckMate-816 in patients with removable non-small cell lung cancer (NSCLC) reached the primary end of the pathological complete remission (pCR). The results showed that the number of patients who received a combination of Odivo (Navuliyu monotherapy) before surgery who surgically removed the specimen and did not detect cancer cells was significantly higher than in patients who received chemotherapy alone. CheckMate-816 became the first and only phase III clinical study to confirm that immunosuppressant combination chemotherapy could benefit patients with non-metastasis non-small cell lung cancer as a new complementary treatment.In the study, patients in the trial group received three cycles of Odivo combined chemotherapy prior to surgery, which is also the standard number of treatment cycles for the new complementary treatment. The safety of Odivo combined chemotherapy is consistent with previous studies of non-small cell lung cancer.Dr Mark Awad, clinical director of the Lowy Chest Oncology Centre at the Dana-Farber Cancer Institute, said: "Up to half of patients with non-metastasis lung cancer who undergo surgery will relapse. Previously, Odivo has been shown to benefit from complementary or postoperative treatment in other types of cancer. Now, based on a positive checkMate-816 result, Odivo is expected to be a new complementary treatment option for patients with small cell lung cancer. We will continue to follow up on the use of Odevo combined chemotherapy in this trial for the case of patients with cutable cell lung cancer, and hope that improvements in pathological full remission will prolong the patient's event-free survival and ultimately the total lifetime. Dr. Abderrahim Oukessou, Vice President and Head of Chest Tumor Development atCentennial, said, "The results of the CheckMate-816 study demonstrate once again the strong advantages of Pershing Meischweig in the field of chest tumor therapy, and a joint Odivo-based treatment has been shown to improve the total survival of patients with metastasis non-small cell lung cancer and non-removable malignant thoracic mesothelioma patients. In addition, these data further enhance our scientific understanding of immunotherapy in the treatment of different early-stage tumors, as the body's immune system is better able to respond, which is expected to change the outcome of treatment in patients. Thank you to the patients and researchers who participated in this trial.

will complete a comprehensive assessment of the available data from the CheckMate-816 study, present the results with researchers at an upcoming medical conference, and discuss potential registration pathways with health regulators. The CheckMate-816 study is still ongoing to assess the event-free lifetime (EFS) and key secondary endpoints of another major study end, which remains blind to the company.In the field of non-metastasis non-small cell lung cancer, Shishi Shiguibao and partners are working together to explore the use of immunotherapy during new ancillary, assisted or peri-surgical periods, as well as its association with simultaneous chemotherapy. To date, new complementary or complementary treatments have been shown in four tumor types, including lung cancer, bladder cancer, esophageal cancer/gastroesophageal connecting cancer and melanoma.

about The CheckMate-816Checkmate-816 is a randomized, open-label, multi-center Phase III clinical study designed to assess the efficacy of Odivo combined chemotherapy for new complementary treatments in patients with cut-out cell lung cancer compared to single-use chemotherapy. In the main analysis, 358 patients were randomly treated with Odivo (360 mg) before surgery in combination with platinum-based bi-drug chemotherapy based on histological credit type (once every 3 weeks, up to 3 cycles), or either single-use double-drug chemotherapy with platinum (once every 3 weeks, up to 3 cycles). The main study endpoints are pathological complete remission (pCR) and event-free lifetime (EFS), with key secondary endpoints including total lifetime (OS), primary pathological mitigation (MPR), and time to death or distant transfer.

about lungLung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer and small cell lung cancer are the two main types of lung cancer, of which non-small cell lung cancer (NSCLC) is the most common, accounting for 84% of all confirmed cases. Most NSCLC patients (about 60%) have not metastasis at the time of diagnosis. Although many patients with non-metastasis non-small cell lung cancer can be cured surgically, 30 to 55 percent of patients will relapse and die of the disease after surgery. A variety of treatment options are therefore required, including preoperative (new complementary treatment) and/or postoperative (assisted therapy) to improve the patient's long-term survival. (Biological exploration)